NAMS
NAMS
NL00150012L7
NewAmsterdam Pharma Company N.V
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±61.6% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.1x).

Beta (Market Relation)
0.1x
Defensive
Volatility (5Y p.a.)
61.6% p.a.
5-Year Horizon
Max Drawdown (5Y)
-66.2%
5-Year Horizon
Sharpe Ratio
0.23
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -35.3%
3 Years 67.4% -49.0% 0.56 +40%
5 Years 61.6% -66.2% 0.23 +16.7%
10 Years — — — —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Elevated Short-Term Volatility: 3Y volatility (67.4%) is noticeably higher than the 5Y average (61.6%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (61.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -66.2% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
-
Audit Risk
-
Board Risk
-
Short Ratio
11.99
ende